Inflammatory bowel disease

Many people with Crohn’s disease or ulcerative colitis use biologic drugs; new clinical and real-world data about a subcutaneous infliximab option could affect treatment choice, switching decisions, and practical use in...

The review links ER stress and mitochondrial dysfunction to core IBD processes (inflammation, barrier damage, cell death) and highlights MERCs as an integrated signaling hub, suggesting new biomarker and therapeutic...

Protein biomarkers that predict IBD years before diagnosis could enable earlier detection, inform risk-stratified monitoring, and reveal early disease pathways that might be targeted to prevent or delay onset.

This study identifies a new experimental compound (z18) that reduced inflammation in cell studies and mouse models of ulcerative colitis, suggesting a potential new avenue for IBD drug discovery.

The paper reports novel ibuprofen-derived compounds that reduce inflammation and restore intestinal immune balance in preclinical models of ulcerative colitis, suggesting a potential new drug-development direction that...

The paper suggests a specific molecule, MXRA7, links macrophage M1 polarization and epithelial pyroptosis—two processes implicated in ulcerative colitis tissue damage. If validated, this could point to new targets for...

The study points to a specific microbiome-derived micronutrient pathway (queuosine/queuine) that appears reduced in IBD, which could help explain part of microbiome-related changes in intestinal cells and suggest new...

Children diagnosed with IBD can develop other immune-related diseases, growth and weight problems, skin conditions, and serious infections over time. Knowing the frequency and risk factors helps families and clinicians...

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from New England...

If confirmed, an existing diabetes drug class (SGLT2 inhibitors) could offer an adjunct anti-inflammatory option for people with mild-to-moderate ulcerative colitis and might affect symptoms, biomarkers, and quality of...

This study reports a new engineered oral probiotic delivery system that may increase probiotic survival, target inflamed colon tissue, and change the gut microbiome in ways that reduced colitis in mice — a potential...

Based on the title and source metadata, this appears to be an opinion or commentary related to Inflammatory bowel disease and Access, cost, and policy. The original article is from Inflammatory bowel diseases.

Physical activity is linked to general health and quality of life. If people with IBD—particularly those with more severe CD—are less active, tailored support could help improve wellbeing and manage disease-related...

Diarrhea is a common, burdensome symptom in IBD. This study suggests that inflammation-linked defects in enterocyte differentiation and reduced ion transporter expression may help explain persistent diarrhea and that...

Patients and clinicians considering long-term use of mirikizumab for Crohn's disease may find evidence here that quality of life and common symptoms (fatigue, abdominal pain, stool frequency) can remain improved out to...

Late-stage (Phase 3) AFFIRM data for subcutaneous Skyrizi in Crohn’s disease are being presented publicly — that could lead to new treatment options if regulators approve expanded indications, and it influences...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Symptoms and flares. The original article is from msn.com.

Cure8 could only read part of this source from tampabay28.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness.

Many people with Crohn’s experience inflammation outside the gut that can affect joints, eyes, skin, gallbladder, kidneys, and bones. Recognizing these signs can help patients and clinicians connect seemingly unrelated...

This study links altered autophagy genes (ATG5, ATG16L1) in Crohn’s disease and ulcerative colitis with modulation by the gut bacterium Akkermansia muciniphila and its extracellular vesicles, suggesting a possible...

Intestinal fibrosis can cause strictures and obstructive complications that often lead to surgery. Research identifying the cellular drivers and druggable pathways could guide development of treatments to prevent or slow...

People with ulcerative colitis often face trial‑and‑error when starting advanced therapies. THAMES‑IBD aims to find biological and psychosocial markers that predict who will respond, which could eventually make treatment...

The study found higher recorded rates of hidradenitis suppurativa in people with Crohn’s disease and psoriatic arthritis, and a smaller increase in ulcerative colitis, suggesting clinicians should consider asking about...

Positive phase 3 results for a subcutaneous risankizumab induction regimen may expand access to an IL‑23 p19 therapy option that avoids IV induction and showed strong short-term remission and endoscopic response rates in...

Positive Phase 3 data for Skyrizi in Crohn’s could affect treatment options and access if regulators expand the drug’s label and insurers update coverage; for patients and clinicians it may signal an additional biologic...

The timing of depression versus GI diagnoses differs by condition: depression commonly comes before IBS but often follows Crohn’s disease. That matters because it suggests different gut–brain pathways and could change...

Fusing blood tests, CT enterography radiomics, and deep-learning analysis of deep small-bowel endoscopy images may improve detection of active small-bowel Crohn’s disease — a common clinical challenge because many...

This analysis suggests a subcutaneous formulation of infliximab may lead to better clinical and endoscopic outcomes than intravenous infliximab for ileal-involved Crohn’s disease, which could affect treatment choices and...

Positive Phase 3 data for a subcutaneous formulation of risankizumab (SKYRIZI) in Crohn’s disease could expand treatment options for people with moderate-to-severe Crohn’s and influence prescribing and insurance coverage...

This registry study offers real-world data on ozanimod effectiveness, persistence, and safety in UC patients, which can help patients and clinicians set expectations beyond clinical trial settings.

Phase III AFFIRM results suggest a subcutaneous risankizumab regimen may increase endoscopic remission in Crohn’s disease, which matters for patients and clinicians weighing biologic options and for regulatory approval...

A Phase 3 positive result for subcutaneous SKYRIZI could expand treatment options for people with Crohn’s disease by offering a more convenient dosing route and may affect how available drugs like Rinvoq are used. It...

This study describes a prototype smart oral capsule that senses colonic inflammation and releases budesonide locally, which could reduce systemic exposure and allow on‑demand, lesion‑specific treatment if translated to...

Telenursing is increasingly used for chronic IBD care; understanding the limits and system factors that affect remote assessment matters because it influences how reliably nurses can detect and respond to flares and...

Cure8 found this source from app.dealroom.co, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full details.

This study follows people from diagnosis and shows that about half achieve clinically meaningful improvements in quality of life by 3 years, but many remain below general population norms.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Inflammatory Bowel Diseases.

Noninvasive imaging that better separates inflammation from fibrosis and detects penetrating complications could change monitoring and treatment decisions in IBD and reduce radiation exposure for patients needing...

The study suggests a fermented seaweed-derived fiber reduced inflammation and oxidative stress in cells and a mouse colitis model and modified gut microbiota and short-chain fatty acids, which could guide future dietary...

Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...

The study suggests psychological (emotional) stress can worsen colitis-like inflammation via GSK3β-mediated neuroimmune changes, and that a probiotic (VSL#3) reduced many adverse effects in mice — relevant to...

The analysis helps compare multiple advanced therapies when head‑to‑head trials are lacking, which may inform drug selection for induction and maintenance in moderate‑to‑severe UC, including for patients who have failed...

The paper suggests serum bilirubin levels statistically explain a meaningful fraction of the link between gut Enterobacterales abundance and endoscopic disease activity in UC, which may point to biologic pathways or...

This study points to possible differences in fiber intake and the food sources of tryptophan between IBD patients and healthy people—factors that could be relevant for future dietary guidance or research, but the results...

The study explores whether blood redox biomarkers relate to short- and long-term response to infliximab or vedolizumab, which could help predict who benefits from these biologics. It also suggests a link between...

Automated Lewis score estimation could make capsule endoscopy readings faster and more consistent, which may help track small-bowel Crohn disease activity. This study shows preliminary feasibility but not readiness for...

Decisions about when to build an ileal pouch after emergency colectomy matter to patients because timing could affect recovery, complications, and long-term pouch function. This study suggests timing within or after 6...

TG2 produced by intestinal myofibroblasts may drive fibrosis and strictures in Crohn's disease independently of inflammation; blocking TG2 reduced fibrosis in lab and mouse models, pointing to a possible new...